Can You Get Medical Cannabis on NHS Prescription? The Truth

The Paradox of NHS Medical Cannabis: Legal Yet Rare
Since November 2018, cannabis-derived medications have been technically legal to prescribe on the NHS in the United Kingdom. Yet nearly six years later, the number of patients receiving NHS prescriptions remains vanishingly small. This disconnect between legality and accessibility has created a frustrating situation for patients and healthcare professionals alike, forcing many sufferers to turn to private practitioners or remain untreated.

Epidyolex: The Exception That Proves the Rule
Epidyolex, a cannabidiol product used to treat severe childhood epilepsy, represents the primary success story of NHS cannabis prescribing. This medication, approved specifically for treating seizures in Dravet syndrome and Lennox-Gastaut syndrome, is relatively readily available through the NHS. Parents of affected children have been able to access this life-changing treatment through standard NHS pathways, making Epidyolex the clearest example of how medical cannabis can work within the NHS framework when there is sufficient clinical evidence and regulatory approval.

Sativex: Licensed but Practically Unavailable

The situation with Sativex, a nabiximols spray approved for treating multiple sclerosis-related muscle spasticity, tells a different story. Although Sativex is licensed and technically available on the NHS, prescriptions are extraordinarily rare. Most NHS trusts have effectively implemented policies making the medication unavailable to patients, citing cost concerns and lack of clinical evidence sufficient to justify its use. Patients who might benefit from Sativex frequently discover that their NHS trust simply will not prescribe it, leaving them with no recourse within the public system.

Individual Funding Requests: A Bureaucratic Hurdle

Patients seeking cannabis-based treatments for conditions not covered by standard NHS pathways can apply for Individual Funding Requests (IFRs). This process requires clinicians to make a case to their local commissioning body for why an individual patient should receive funding for a particular treatment. However, IFRs are notoriously difficult to obtain for cannabis medications. Success rates remain low, and the process involves lengthy delays whilst committees deliberate. The burden of proof falls heavily on patients and their doctors, with commissioners typically demanding evidence that meets the highest standards before approving funding.

NHS Prescribing Statistics: Numbers That Tell a Story

The prescribing statistics paint a stark picture. As of recent data collection, only a few hundred patients across the entire NHS have received prescriptions for cannabis-based medications. This represents an extraordinarily small fraction of the millions of NHS patients who might potentially benefit from such treatments. The contrast between the legal permission granted in 2018 and actual prescribing volumes demonstrates the vast gulf between policy and practice.

What Would Change NHS Prescribing Practices?

Several developments could potentially unlock wider NHS prescribing of medical cannabis. First, more robust clinical trial evidence would help—large-scale studies demonstrating efficacy for specific conditions would provide commissioners with greater confidence. Second, clearer NICE (National Institute for Health and Care Excellence) guidance specifically addressing medical cannabis would streamline prescribing decisions. Third, cost reduction through domestic production or bulk purchasing agreements could allay financial concerns. Finally, pressure from professional bodies and regulatory changes could shift institutional attitudes toward these medications.

Patient Advocacy and Policy Change

Patient advocacy groups have played an increasingly vocal role in pushing for NHS reform. Organisations representing epilepsy sufferers, MS patients, and chronic pain patients have lobbied Parliament and media outlets, highlighting cases where patients benefit dramatically from medical cannabis yet cannot access it through the NHS. This grassroots activism continues to build political pressure for policy reform, though progress remains slow.

The NHS Versus Private Costs

The financial barriers facing patients are substantial. Private medical cannabis prescriptions typically cost between £600 and £1,500 per month, placing treatments far beyond the reach of many patients. Private consultations with specialists in cannabis medicine add further expense. NHS prescriptions, when accessible, would cost patients only the standard prescription fee of approximately £11.65 in England. This massive cost differential means that only relatively affluent patients can access private medical cannabis, whilst NHS patients with the same conditions receive nothing.

Conclusion: Waiting for Momentum

Medical cannabis remains trapped in a peculiar limbo within the UK healthcare system—legally available but practically inaccessible for most patients. Until evidence accumulates, guidance clarifies, and institutional attitudes shift, this situation looks unlikely to change dramatically in the near future.